Compounds > 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Diabetic Glomerulosclerosis

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Diabetic Glomerulosclerosis in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's3 (60.00)29.6817
2010's0 (0.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Abdel-Hakeem, EA; Hafez, HM; Hassanein, H1
Martell, SK; McLennan, SV; Yue, DK1
Inaba, K; Kasuga, M; Kojima, H; Kusunoki, H; Liu, BF; Miyata, S; Miyazaki, H; Ohara, T; Suzuki, K; Uriuhara, A; Yamashita, Y1
Cheng, YS; Fan, WK; Fang, YH; Yan, SG; Yu, YW; Zhang, JP; Zheng, JF; Zhou, SX1
Castellino, P; DeFronzo, RA; Tuttle, KR1

Other Studies

5 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Diabetic Glomerulosclerosis

ArticleYear
Rupatadine, a dual antagonist of histamine and platelet-activating factor (PAF), attenuates experimentally induced diabetic nephropathy in rats.
    Naunyn-Schmiedeberg's archives of pharmacology, 2020, Volume: 393, Issue:8

    Topics: Animals; Blood Glucose; Cyclin-Dependent Kinase Inhibitor p21; Cyproheptadine; Cystatin C; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Histamine Antagonists; Kidney; Male; Oxidative Stress; Platelet Activating Factor; Rats; Streptozocin; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53

2020
Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy.
    Diabetes, 2002, Volume: 51, Issue:8

    Topics: Cells, Cultured; Culture Media, Conditioned; Diabetic Nephropathies; DNA Primers; Fetus; Gelatinases; Glomerular Mesangium; Glycosylation; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinases; Platelet Activating Factor; Reverse Transcriptase Polymerase Chain Reaction; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transforming Growth Factor beta

2002
Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy.
    Diabetes care, 2003, Volume: 26, Issue:6

    Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Biomarkers; Chromatography, High Pressure Liquid; Deoxyglucose; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Fasting; Glycated Hemoglobin; Glycosylation; Humans; Middle Aged; Platelet Activating Factor; Reference Values

2003
[Relationship between serum vWF and PAF in type 2 diabetic patients and diabetic nephropathy].
    Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, 2005, Volume: 25, Issue:6

    Topics: Adult; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Male; Middle Aged; Platelet Activating Factor; von Willebrand Factor

2005
Diabetic nephropathy.
    Current therapy in endocrinology and metabolism, 1994, Volume: 5

    Topics: Adrenergic beta-Antagonists; Aldehyde Reductase; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diet, Protein-Restricted; Diuretics; Exercise; Glycosylation; Guanidines; Humans; Hypertension; Platelet Activating Factor; Rats; Somatostatin; Weight Loss

1994